196-210 of 344
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
- advertisement
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
CME/CESecond-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Aditya Bardia, MD, MPH, FASCO
Tiffany Traina, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Sandra Swain, MD
Virginia Kaklamani, MD
- advertisement
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®Differential Diagnosis of Indolent Systemic Mastocytosis
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
MinuteCE®Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
